Catalog No.: PC-24572Not For Human Use, Lab Use Only.
Dabrafenib (GSK2118436) is potent, selective ATP-competitive inhibitor of Raf with IC50 of 5 nM and 0.6 nM for C-Raf and B-Raf V600E respectively, also potently inhibits RIPK3 with IC50 of 28 nM.
Dabrafenib (GSK2118436) is potent, selective ATP-competitive inhibitor of Raf with IC50 of 5 nM and 0.6 nM for C-Raf and B-Raf V600E respectively, also potently inhibits RIPK3 with IC50 of 28 nM. Dabrafenib displayed highly selective inhibition on RIP3 over RIP1, RIP2 and RIP5. Dabrafenib rescued cells from RIP3-mediated necroptosis induced by the necroptosis-induced combinations, that is, tumor necrosis factor (TNF)α, TNF-related apoptosis-inducing ligand or Fas ligand plus Smac mimetic and the caspase inhibitor z-VAD. Dabrafenib decreased the RIP3-mediated Ser358 phosphorylation of mixed lineage kinase domain-like protein (MLKL) and disrupted the interaction between RIP3 and MLKL.
